452 related articles for article (PubMed ID: 25691618)
1. First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension.
Böhm M; Mahfoud F; Ukena C; Hoppe UC; Narkiewicz K; Negoita M; Ruilope L; Schlaich MP; Schmieder RE; Whitbourn R; Williams B; Zeymer U; Zirlik A; Mancia G;
Hypertension; 2015 Apr; 65(4):766-74. PubMed ID: 25691618
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial.
Bhatt DL; Vaduganathan M; Kandzari DE; Leon MB; Rocha-Singh K; Townsend RR; Katzen BT; Oparil S; Brar S; DeBruin V; Fahy M; Bakris GL;
Lancet; 2022 Oct; 400(10361):1405-1416. PubMed ID: 36130612
[TBL] [Abstract][Full Text] [Related]
3. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial.
Bakris GL; Townsend RR; Flack JM; Brar S; Cohen SA; D'Agostino R; Kandzari DE; Katzen BT; Leon MB; Mauri L; Negoita M; O'Neill WW; Oparil S; Rocha-Singh K; Bhatt DL;
J Am Coll Cardiol; 2015 Apr; 65(13):1314-1321. PubMed ID: 25835443
[TBL] [Abstract][Full Text] [Related]
4. Effect of Alcohol-Mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Medications: Primary Results From the TARGET BP I Randomized Clinical Trial.
Kandzari DE; Weber MA; Pathak A; Zidar JP; Saxena M; David SW; Schmieder RE; Janas AJ; Langer C; Persu A; Mendelsohn FO; Ameloot K; Foster M; Fischell TA; Parise H; Mahfoud F
Circulation; 2024 Jun; 149(24):1875-1884. PubMed ID: 38587557
[TBL] [Abstract][Full Text] [Related]
5. Twenty-Four-Hour Blood Pressure Monitoring to Predict and Assess Impact of Renal Denervation: The DENERHTN Study (Renal Denervation for Hypertension).
Gosse P; Cremer A; Pereira H; Bobrie G; Chatellier G; Chamontin B; Courand PY; Delsart P; Denolle T; Dourmap C; Ferrari E; Girerd X; Michel Halimi J; Herpin D; Lantelme P; Monge M; Mounier-Vehier C; Mourad JJ; Ormezzano O; Ribstein J; Rossignol P; Sapoval M; Vaïsse B; Zannad F; Azizi M
Hypertension; 2017 Mar; 69(3):494-500. PubMed ID: 28115517
[TBL] [Abstract][Full Text] [Related]
6. Outcomes Following Radiofrequency Renal Denervation According to Antihypertensive Medications: Subgroup Analysis of the Global SYMPLICITY Registry DEFINE.
Mahfoud F; Mancia G; Schmieder RE; Ruilope L; Narkiewicz K; Schlaich M; Williams B; Ribichini F; Weil J; Almerri K; Sharif F; Lauder L; Wanten M; Fahy M; Böhm M
Hypertension; 2023 Aug; 80(8):1759-1770. PubMed ID: 37317866
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of renal denervation in elderly patients with resistant hypertension.
Ziegler AK; Bertog S; Kaltenbach B; Id D; Franke J; Hofmann I; Vaskelyte L; Sievert H
Catheter Cardiovasc Interv; 2015 Aug; 86(2):299-303. PubMed ID: 23983010
[TBL] [Abstract][Full Text] [Related]
8. Transurethral Renal Pelvic Denervation: A Feasibility Trial in Patients with Uncontrolled Hypertension.
Hering D; Nikoleishvili D; Imedadze A; Dughashvili G; Klimiashvili Z; Bekaia E; Shengelia T; Kobalava M; Goguadze O; Emukhvari T; Druker V; Sackner-Bernstein J; Weber MA
Hypertension; 2022 Dec; 79(12):2787-2795. PubMed ID: 36254733
[TBL] [Abstract][Full Text] [Related]
9. Pulse Wave Velocity Predicts Response to Renal Denervation in Isolated Systolic Hypertension.
Fengler K; Rommel KP; Hoellriegel R; Blazek S; Besler C; Desch S; Schuler G; Linke A; Lurz P
J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28515119
[TBL] [Abstract][Full Text] [Related]
10. Renal artery denervation for treatment of patients with self-reported obstructive sleep apnea and resistant hypertension: results from the Global SYMPLICITY Registry.
Linz D; Mancia G; Mahfoud F; Narkiewicz K; Ruilope L; Schlaich M; Kindermann I; Schmieder RE; Ewen S; Williams B; Böhm M;
J Hypertens; 2017 Jan; 35(1):148-153. PubMed ID: 27906840
[TBL] [Abstract][Full Text] [Related]
11. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension.
Fadl Elmula FE; Hoffmann P; Larstorp AC; Fossum E; Brekke M; Kjeldsen SE; Gjønnæss E; Hjørnholm U; Kjaer VN; Rostrup M; Os I; Stenehjem A; Høieggen A
Hypertension; 2014 May; 63(5):991-9. PubMed ID: 24591332
[TBL] [Abstract][Full Text] [Related]
12. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial.
Kandzari DE; Böhm M; Mahfoud F; Townsend RR; Weber MA; Pocock S; Tsioufis K; Tousoulis D; Choi JW; East C; Brar S; Cohen SA; Fahy M; Pilcher G; Kario K;
Lancet; 2018 Jun; 391(10137):2346-2355. PubMed ID: 29803589
[TBL] [Abstract][Full Text] [Related]
13. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension.
Desch S; Okon T; Heinemann D; Kulle K; Röhnert K; Sonnabend M; Petzold M; Müller U; Schuler G; Eitel I; Thiele H; Lurz P
Hypertension; 2015 Jun; 65(6):1202-8. PubMed ID: 25824248
[TBL] [Abstract][Full Text] [Related]
14. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension.
Mahfoud F; Ukena C; Schmieder RE; Cremers B; Rump LC; Vonend O; Weil J; Schmidt M; Hoppe UC; Zeller T; Bauer A; Ott C; Blessing E; Sobotka PA; Krum H; Schlaich M; Esler M; Böhm M
Circulation; 2013 Jul; 128(2):132-40. PubMed ID: 23780578
[TBL] [Abstract][Full Text] [Related]
15. Renal denervation therapy for the treatment of resistant hypertension: a position statement by the Canadian Hypertension Education Program.
Khan NA; Herman RJ; Quinn RR; Rabkin SW; Ravani P; Tobe SW; Feldman RD; Wijeysundera HC; Padwal RS;
Can J Cardiol; 2014 Jan; 30(1):16-21. PubMed ID: 24269056
[TBL] [Abstract][Full Text] [Related]
16. Renal sympathetic denervation as second-line therapy in mild resistant hypertension: a pilot study.
Kaltenbach B; Franke J; Bertog SC; Steinberg DH; Hofmann I; Sievert H
Catheter Cardiovasc Interv; 2013 Feb; 81(2):335-9. PubMed ID: 22807098
[TBL] [Abstract][Full Text] [Related]
17. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3.
Bakris GL; Townsend RR; Liu M; Cohen SA; D'Agostino R; Flack JM; Kandzari DE; Katzen BT; Leon MB; Mauri L; Negoita M; O'Neill WW; Oparil S; Rocha-Singh K; Bhatt DL;
J Am Coll Cardiol; 2014 Sep; 64(11):1071-8. PubMed ID: 24858423
[TBL] [Abstract][Full Text] [Related]
18. Safety and performance of the second generation EnligHTN™ Renal Denervation System in patients with drug-resistant, uncontrolled hypertension.
Worthley SG; Wilkins GT; Webster MW; Montarello JK; Delacroix S; Whitbourn RJ; Warren RJ
Atherosclerosis; 2017 Jul; 262():94-100. PubMed ID: 28531827
[TBL] [Abstract][Full Text] [Related]
19. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study.
Krum H; Schlaich M; Whitbourn R; Sobotka PA; Sadowski J; Bartus K; Kapelak B; Walton A; Sievert H; Thambar S; Abraham WT; Esler M
Lancet; 2009 Apr; 373(9671):1275-81. PubMed ID: 19332353
[TBL] [Abstract][Full Text] [Related]
20. Catheter-based renal denervation for resistant hypertension: 12-month results of the EnligHTN I first-in-human study using a multielectrode ablation system.
Papademetriou V; Tsioufis CP; Sinhal A; Chew DP; Meredith IT; Malaiapan Y; Worthley MI; Worthley SG
Hypertension; 2014 Sep; 64(3):565-72. PubMed ID: 24935940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
